BioNTech, Pfizer seek declaratory judgment against CureVac COVID-19 vaccine patent infringement claims
JURIST
JULY 26, 2022
The companies seek to quell claims by CureVac of intellectual property violations. Pfizer developed over 3 million doses in 2021 and expects 4 million in 2022. In January, CureVac began discussions with BioNTech and Pfizer over intellectual property rights. CureVac now faces over $1 billion in debt. 11,149,278.
Let's personalize your content